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Catherine E Vialle-Valentin*, Robert F LeCates, Fang Zhang and Dennis Ross-DegnanAbstract
Objectives: To evaluate the determinants of compliance with national policies recommending Artemisinin
Combination Therapy (ACT) for the treatment of uncomplicated malaria in the community.
Methods: We used data from Gambia, Ghana, Kenya, Nigeria, and Uganda national household surveys that were
conducted with a standardized World Health Organization (WHO) methodology to measure access to and use of
medicines. We analyzed all episodes of acute fever reported in the five surveys. We used logistic regression models
accounting for the clustered design of the surveys to identify determinants of seeking care in public healthcare
facilities, of being treated with antimalarials, and of receiving ACT.
Results: Overall, 92% of individuals with a febrile episode sought care outside the home, 96% received medicines,
67% were treated with antimalarials, and 16% received ACT. The choice of provider was influenced by perceptions
about medicines availability and affordability. In addition, seeking care in a public healthcare facility was the single
most important predictor of treatment with ACT [odds ratio (OR): 4.64, 95% confidence intervals (CI): 2.98–7.22,
P < 0.001]. Children under 5 years old were more likely than adults to be treated with antimalarials [OR: 1.28,
CI: 0.91–1.79, not significant (NS)] but less likely to receive ACT (OR: 0.80, CI: 0.57–1.13, NS).
Conclusions: Our results confirm the high prevalence of presumptive antimalarial treatment for acute fever,
especially in public healthcare facilities where poor people seek care. They show that perceptions about access to
medicines shape behaviors by directing patients and caregivers to sources of care where they believe medicines
are accessible. The success of national policies recommending ACT for the treatment of uncomplicated malaria
depends not only on restricting ACT to confirmed malaria cases, but also on ensuring that ACT is available and
affordable for those who need it.
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Artemisinin-Combination Therapy (ACT) is considered
the most effective pharmaceutical intervention to con-
trol malaria, in conjunction with long-lasting insecticidal
nets (LLIN), indoor residual spraying (IRS) and intermit-
tent presumptive treatment (IPT) with Sulfadoxine/Pyri-
methamine (SP) during pregnancy [1-5]. In recent years,
national policies have endorsed first-line treatment with
ACT for uncomplicated malaria in countries at high risk* Correspondence: catherine.vialle@post.harvard.edu
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unless otherwise stated.of malaria. Implementation of such policies presents con-
siderable challenges on the supply side to ensure adequate
funding through international subsidies, sufficient manu-
facturing of co-blistered combinations in line with inter-
nationally recommended standards, and uninterrupted
distribution [6,7]. On the demand side, deep-rooted treat-
ment behaviors and high ACT retail prices have slowed
the adoption of the policy by healthcare providers and pa-
tients alike [8,9].
ACTWatch household surveys conducted at the start of
the Affordable Medicines Facility-malaria (AMFm) initia-
tive found that less than half of children under 5 years old
with fever received ACT [10-13]. Little evidence existsentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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givers regarding national recommendations to switch from
well-established practices to new treatment paradigms.
Yet, a better understanding of the factors slowing the
adoption of ACT is needed [14]. The objectives of this
study were to describe the early compliance with national
policies recommending ACT as first-line therapy for sus-
pected malaria and to identify predictors of ACT use in
communities at high risk of malaria. To investigate the
extent of ACT utilization by households and the determi-
nants of ACT use, we analyzed existing data from house-
hold surveys that were conducted with a standard
methodology developed by the World Health Organization
(WHO) to measure medicines access and use in low- and
middle-income countries.
Methods
Survey methodology, data collection and management
The WHO methodology to measure medicines access
and use with standardized rapid cluster sample house-
hold surveys has been previously described [15]. This
study includes five surveys in countries at high risk of
malaria that were conducted with the original WHO
methodology (The Gambia, Nigeria) or the revised
Medicines Transparency Alliance (MeTA) methodology
(Ghana, Kenya, and Uganda). Data collection took place
in August 2007 (Nigeria), October 2007 (The Gambia),
May-June 2008 (Ghana), July-August 2008 (Uganda) and
September-October 2008 (Kenya). The open source soft-
ware EpiData Entry v.2.0 (The EpiData Association,
Odense, Denmark) was used for data entry. All medi-
cines names were entered as collected and their equiva-
lent generic nomenclature was coded with a Microsoft
Exceltm tool based on the WHO 15th Model Essential
Medicines List [16]. All medicines coded 6.531 “antimal-
arial” are included in this analysis.
Analysis
We received anonymized country survey datasets from
local teams after obtaining Harvard Pilgrim Health Care
Institutional Review Board approval to conduct the
study. We imported them into StataSE V.11.2 (Stata-
Corp, College Station, Texas). All analyses used the Sur-
vey commands of Stata to account for the clustered
sample design and to adjust for the disproportioned allo-
cation of sample clusters between the capital (or most
densely populated) region and other areas of a country.
In combined analyses, we weighted each country survey
population equally rather than proportional to country
population size in order to prevent multi-country results
from being dominated by the Nigeria results. At the time
of data collection, the WHO/MeTA surveys did not col-
lect information on malaria diagnostic tests. In the ab-
sence of confirmed diagnosis with a parasite-based test,clinical suspicion of malaria and presumptive treatment
are based on the presence of fever [17,18]. Therefore we
included in our analysis all individuals with acute symp-
toms recorded under the group of symptoms “fever,
headache, hot body”.
We hypothesized that episodes of acute fever would be
treated differently in the public and private sectors be-
cause changes in national antimalarial policies at the
time of the surveys targeted primarily public healthcare
facilities. We used the Stata survey multivariate logistic
regression commands to identify predictors of the deci-
sion to seek care in a public healthcare facility rather
than in the private sector and of subsequent use of anti-
malarials and ACT in presence of acute fever.
Potential predictor variables included in the model
were health services-related (sources of care accessed
during acute fever), household-related (location, socio-
economic status, proximity of healthcare facilities, re-
spondent education, respondent opinions on medicines
access) and patient-related (patient gender, age under
5 years old, associated symptoms, perceived severity of
fever). Socio-economic satus of households was assessed
from the self-reported monthly expenditure quintile; ex-
penditure quintile boundaries were calculated from the
most recent national household economic survey ad-
justed for household size. Households in the lowest
quintile were considered poor; households in the other
quintiles were considered non-poor.
Results
Characteristics of surveyed households
The characteristics of all 5261 surveyed households, in-
cluding prevalence of acute illness, have been previously
described [15]. Table 1 presents the differences observed
between the households surveyed in capitals and in
other parts of the countries, and between poor and non-
poor households. In capital areas, a lower proportion of
households was poor (estimated proportion: 10.8% vs.
35.6%, p < 0.001), situated far from public healthcare fa-
cilities (9.1% vs. 15.3%, p < 0.05), and far from private
healthcare providers (16.3% vs. 35.0%, p < 0.001) or med-
icines retail outlets (7.5% vs.15.3%, p < 0.05). Higher pro-
portions of respondents living in capital areas were
female (66.5% vs. 48.3%, p < 0.001), between 25–50 years
old (76.9% vs. 66.5%, p < 0.001), with education beyond
high school (26.3% vs.18.3%, p < 0.05), and of the opin-
ion that medicines are affordable (53.4% vs. 42.2%,
p < 0.05). Poor households shared many of the attributes
of households outside capital areas. In addition, the pro-
portion of households stocking medicines at home
was lower if households were poor (39.4% vs. 52.6%,
p < 0.001), even though a higher proportion of poor re-
spondents reported an acute illness in the preceding
2 weeks (55.4% vs. 48.7%, p = 0.01).
Table 1 Demographic and socio-economic characteristics of surveyed households




1485 3676 4188 973
Mean household size
(95% Confidence Intervals)
7.0(6.5,7.5) 6.3(5.9,6.8) 6.5(6.1, 6.8) 6.8(5.5, 8.0)
Proportion Estimates Proportion Estimates
(95% Confidence Intervals) (95% Confidence Intervals)
Pearson chi2 Pearson
chi2
Outside Capital 90.6(87.8, 93.4) 67.8(63.3, 72.3) p<0.001 1.00(-,-) 0.0(0.0, 0.0) na
Poor 1.00(-,-) 0.0(0.0, 0.0) na 35.6(31.2, 40.1) 10.8(7.5, 14.1) p<0.001
With children under 15 years old 91.2(89.2, 93.1) 85.4(83.3, 87.6) p<0.001 88.1(86.3, 89.9) 84.2(80.1, 88.4) ns
With children 5 years old 65.6(62.2, 68.9) 59.3(55.8, 62.7) p<0.001 60.5(57.6, 63.4) 62.8(56.0, 69.5) ns
Respondent
Female 49.3(44.5, 54.1) 54.5(51.2, 57.7) ns 48.3(44.7, 51.9) 66.5(61.7, 71.4) p<0.001
Age 25-50 64.7(61.3, 68.2) 71.0(68.5, 73.4) p<0.01 66.5(64.3, 68.7) 76.9(71.8, 82.0) p<0.001
Complete at least primary school 43.7(38.5, 48.9) 63.5(58.7, 68.2) p<0.001 57.0(52.7, 61.4) 59.5(48.7, 70.2) ns
Education high school or above 7.2(5.0, 9.5) 25.8(22.3, 29.2) p<0.001 18.3(15.3, 21.3) 26.3(19.4, 33.3) p<0.05
Opinions
Closet public facility has medicines 40.9(35.6, 46.2) 36.3(32.1, 40.4) ns 38.9(34.8, 43.0) 33.8(25.9, 41.7) ns
Free medicines at public facility 61.4(54.9, 68.0) 50.7(45.5, 56.0) p<0.001 56.0(50.1, 62.0) 47.5(38.1,56.9) ns
Can usually afford medicines needed 35.8(30.9, 40.7) 48.9(44.8, 53.0) p<0.001 42.2(38.3,46.0) 53.4(44.0M,62.8) P<0.05
Distance from closet public health
care facility
Less than 15 mins 49.2(42.2, 55.8) 49.6(45.5,53.7) ns 51.1(46.1,56.0) 44.8(37.1,52.4) ns
Over 1 hour 19.3(14.1, 24.4) 11.4(8.8,13.9) p<0.005 15.3(11.9,18.7) 9.1(4.8,13.3) p<0.05
Distance from closet private health
care provider
Less than 15 mminutes 31.1(25.0, 37.1) 40.7(35.5,45.9) p<0.005 34.2(29.3,39.1) 48.7(36.6,60.8) p=0.01
Over 1 hour 41.8(34.9,48.7) 25.5(21.0,29.9) p<0.001 35.0(29.8,40.2) 16.3(7.0,25.6) p<0.001
Distance from closet private medication
retail outlet
Less tahn 15 minutes 62.1(55.3,68.8) 67.9(63.3,72.6) ns 65.9(60.5,71.4) 67.0(58.4,75.6) ns
Over 1 hour 18.8(13.4,24.2) 11.0(7.7,14.4) p<0.01 15.3(11.4, 19.1) 7.5(1.2,13.8) p<0.05
With medicines at home 39.4(35.1,43.6) 52.6(49.4,55.9) p<0.001 47.6(44.2,51.0) 52.1(46.2,57.9) ns
With anitimarial at home 9.1(7.2,11.0) 10.8(9.2,12.3) ns 10.6(9.0,12.1) 9.4(6.9,11.8) ns
Reporting Illness(es) in past two weeks 55.4(50.4,60.3) 48.7(45.2,52..1) p=0.01 50.5(46.6,54.4) 50.9(44.6,57.3) ns
Reporting fever epidode(s) in past two weeks 37.2(32.9,41.5) 33.7(30.4,36.9) ns 34.1(30.8,37.4) 36.5(29.9,43.1) ns
*Respondent self-seclection into lowest pre-define country-specific expenditure based on data from recent national household surveys reporting per capita Gross
National Income or Consumption.
**The WHO survey methodology calls for surveying the “capital or most densely populated area in the country. The capital region was surveyed in Ghana, Kenya
and Uganda; in Nigeria, logos was selected as the most densely populated area of the country.
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91.8% sought care outside the home, 96.0% took medi-
cines, 67.0% received antimalarials, and 16.2% received
ACT. Several characteristics differed between sick indi-
viduals from households in capital vs. non-capital areas.
In capital areas, lower proportions of respondents re-
ported a severe fever (12.6% vs. 21.8%, p < 0.001), weretreated in a public healthcare facility (43.6% vs. 53.6%,
p < 0.05), received ACT (9.0% vs. 18.5%, p < 0.05) or an-
tibiotics (20.7% vs. 34.8%, p < 0.005). (Table 2) The pro-
portion of sick individuals from poor households who
sought care outside the home was lower (88.3% vs. 93.4,
p < 0.005), the proportion traveling more than one hour
to receive care was higher (23.3% vs. 13.1%, p < 0.001),
Table 2 Demographic characteristics, severity and actions taken for episodes of acute fever in the two weeks
preceding the survey according to socio-economic status and geographic location




652 1384 1671 329
Proportion Estimates
(95% Confindence Intervals)





Gambia 8.2(5.1,13.2) 20.2(12.8,30.4) 6.8(4.3,10.8) 25.9
Ghana 9.0(5.1,15.3) 14.7(10.0,21.0) 15.2(10.1,22.3) 5.6(1.8,16.2)
Kenya 33.9(23.5,46.1) 18.3(12.3,26.4) 29.2(20.7,39.5) 4.3(1.6,11.3)
Negeria 16.4(9.7,26.4) 20..4(14.2,28.4) 21.2(14.5,29.8) 12.7(5.0,28.9)
Uganda 32.5(22.1,44.9) 26.4(18.3,36.1) 27.6(19.3,37.9) 30.5(13.7, 54.9)
Female 52.7(48.3,57.2) 55.9(52.3,59.3) ns 54.1(51.2,57.0) 57.4(50.0,64.4) ns
Age umder 44.4(38.8,50.1) 36.5(33.2,40.0) ns 40.3(36.7,44.1) 34.7(229.9,39.9) ns
Very severe fever 19.6(15.8,24.1) 19.6(17.1,22.4) ns 21.8(19.1,24.9) 12.6(9.5,16.4) p<0.001
Reported associated symptoms ns ns
Upper respiratory (cough, runny nose,
sore throat, earache)
33.5(27.9,39.6) 36.0(31.4,40.8) ns 36.8(32.4,41.4) 30.1(22.7,38.7) ns
Difficulty breathing, fast breathing 7.1(5.1,9.8) 6.0(4.5,7.9) ns 7.1(5.6,9.1) 3.8(2.0,7.3) ns
Gastro-interstinal (diarrhea, nausea,
could not eat)
25.1(20.8,29.9) 22.8(19.0,27.0) ns 23.5(20.5,26.8) 23.5(15.1,34.7) ns
All other symptoms 35.9(28.44.2) 42.2(37.2,47.3) ns 38.7(33.0,44.8) 44.8(35.5,54.4) ns
Actions taken
Sought care outside home 88.3(84.4,91.4) 93.4(91.8,94.8) p<0.005 91.1(88.8,92.9) 94.3(91.6,96.1) ns
traveled more than one hour to recieve care 23.3(16.6,31.6) 13.1(10.6,15.9) p<0.001 17.4(13.7,22.0) 12.5(8.3,18.5) ns
received in a public health facility 52.1(46.1,58.0) 50.8(46.1,55.4) ns 53.6(49.2,57.9) 43.6(33.7,54.0) p<0.05
Treatment
Received medicines 95.3(92.6,97.0) 96.4(94.8,97.5) ns 96.6(95.3,97.5) 94.4(89.5,97.0) ns
obtained all medicines free-of-charge 31.2(25.4,37.7) 30.6(26.1,35.6) ns 32.8(27.7,38.8) 24.4(17.7,32.6) ns
Received antimalarials 64.2(59.1,68.9) 68.3(64.9,71.5) ns 67.5(63.9,70.9) 65.4(59.6,70.8) ns
obtained antimalarials and other medicines
in public facility
36.7(31.1,42.7) 33.5(29.8,37.4) ns 36.7(40.9) 27.5(20.2,36.2) ns
received ACT 18.5(13.9,24.2) 15.2(12.2,18.7) ns 18.5(15.2,22.4) 9.0(4.7,16.7) p<0.05
obtained ACT and other medicines in public
in facility
13.5(9.8,18.5) 10.6(8.3,13.5) ns 14.4(11.5,17.8) 2.7(1.1,6.2) p<0.0001
obtained all medicines including ACT free-of-charge 10.3(7.0,15.0) 6.9(5.0,9.4) ns 9.9(7.4,13.1) 1.7(0.6,4.5) p<0.001
Received antibiotics 31.3(26.9,36.0) 31.4(27.5,35.6) ns 34.8(31.2,38.5) 20.7(14.28.5) p<0.005
Received analgesics or NSAIDs 65.2(59.9,70.2) 70.6(67.3,73.8) p<0.05 69.3(66.2,72.3) 67.6(58.7,75.4) ns
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lower (65.2% vs. 70.6%, p < 0.05) than in the group from
non-poor households.
Use of antimalarials and ACTs to treat acute fever
The profile of antimalarials used to treat acute fever var-
ied greatly across surveys, and the proportion of fevers
treated with ACT varied from none in Gambia to 26.6%
in Ghana. In the Gambia survey, chloroquine, SP, andquinine were the only antimalarials reported to treat
fever, while a variety of different antimalarial medica-
tions were documented in the four other surveys.
(Table 3) When ACT was used, the choice of artemisinin
combination usually appeared to be consistent with na-
tional policies in effect at the time of the surveys: i.e.,
artesunate + amodiaquine (AS + AQ) in Ghana, arte-
mether + lumefantrine in Kenya, Nigeria, and Uganda.
The proportion of individuals with acute fever who
Table 3 Use of antimalarials among individuals with acute fever and treated with antimalarials (proportion
estimates & 95% confidence intervals)
Gambia Ghana Kenya Nigeria Uganda
Artemisinin-combination theraphy
artemether_amiodaquine - - - 0%(0%, 1%) -
artemether_lumefantrine - 4%(-1%) 30%(21%,39%) 8%(4%,11%) 36%(26%,46%)
artesunate_amodiaquine - 32%(21%,42%) - 0%(0%,1%) -
artesunate_mefloquine - - 0%(0%,1%) - -
dihydroartemisinin_piperaquine - 5%(1%,9%) 0%(0%,1%) - 1%(0%,2%)
Other Antimalarials
SP 64%(54%,74%) 4%(0%,7%) 13%(6%,20%) 9%(3%,15%) 9%(6%,13%)
chloroquine 97%(95%,100%) 8%(1%,16%) 1%(0%,2%) 39%(29%,48%) 18%(12%,24%)
amodiaquine - 21%(13%,29%) 13%(8%,18%) 0%(0%,1%) 4%(1%,7%)
antimalarial, unspecified - 19%(11%,27%) 33%(25%,42%) 38%(27%,48%) 24%(13%,35%)
quinine 1%(0%,1%) 4%(-1%,8%) 11%(6%,15%) 1%(0%,3%) 21%(17%,25%)
artemether - 3%(0%,5%) - 3%(0%,6%) 1%(0%,1%)
artemisinin - - 1%(0%,2%) 1%(0%,2%) -
artesunate - 9%(4%,14%) - 5%(2%,8%) -
chloroquine_SP 1%(0%,2%) - - - 0%(0%,1%)
dihydroartemisinin - - 2%(0%,3%) 1%(0%,1%) -
halofantrine - - - 1%(0%,2%) -
mefloquine - - - 0%(0%,1%) -
quinine_SP - - 2%(0%,3%) - -
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in a public healthcare facility was consistently higher in
the group of patients who received ACT (Figure 1).
Predictors of seeking care in a public healthcare facility
Having hypothesized that the point of care would be a
key determinant for receiving ACT, we examined which
factors led people to seek care in a public healthcare fa-
cility. The strongest determinant was proximity: com-
pared to people living within 15 min of a public health
facility, people were less likely to seek care in the public
sector if their home was located between 15 minutes
and 1 hour away (odds ratio 0.40; 95% confidence inter-
vals (0.29–0.56), P < 0.001] and even less likely when
travel time was over one hour away [0.21, (0.14–0.33),
P < 0.001]. (Table 4) The further away people lived from
a private medicines retail outlet, the more likely they
were to seek care in a public healthcare facility: from
[1.20, (0.83–1.75), not significant (NS)] when travel time
to a private outlet was between 15 minutes and one hour
to [1.57, (1.06–2.33), P < 0.05] when travel time increased
to over one hour.
While people were also more likely to seek care in a
public healthcare facility if they lived in non-capital re-
gions (2.14, (1.36–3.37), P < 0.01), education and povertydid not appear to directly affect their choice of source of
care. Other factors that increased the likelihood of seek-
ing care in a public healthcare facility were the percep-
tions that the closest public healthcare facility usually
carries the medicines needed [1.47, (1.09–1.99), P < 0.05]
and that it is possible to obtain free medicines in public
healthcare facilities [1.91, (1.45–2.51), P < 0.001]. Re-
spondents who felt that they could afford medicines
were less likely to visit a public facility [0.65, (0.48–0.89),
P < 0.01]. Finally, the likelihood of visiting a public facil-
ity increased with the perceived severity of illness [from
1.36, (1.02–1.82), P < 0.05 for illness perceived as moder-
ately severe to 1.46, (1.01–2.11), P < 0.05 for illness per-
ceived as very severe].
Predictors of antimalarial and ACT use for acute fever
Seeking care in a public health facility increased the like-
lihood of receiving an antimalarial for a febrile episode
[1.67, (1.24–2.25), P < 0.01], as did living outside of
a country’s capital area [1.52, (1.00–2.30), P < 0.05].
(Table 4) In addition, the perceived severity of illness
and presence of gastro-intestinal symptoms increased
the odds of receiving antimalarials [1.82, (1.38–2.40),
P < 0.001 and 1.40, (1.01–1.94), P < 0.05 respectively],
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Obtained all medicines in a private retail outlet
Figure 1 Sources of antimalarials in the community.
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(0.44–0.79), P < 0.001 and 0.61, (0.46–0.82), P < 0.001
respectively].
By far, the most significant determinant of receiving
ACT was being treated in a public healthcare facility
[4.64, (2.98–7.22), P < 0.001]. Respondent education be-
yond high school was also associated with ACT use
[2.67, (1.74–4.11), P < 0.001]. The presence of associated
URI symptoms decreased the odds of receiving ACT
[0.68, (0.48–0.99), P < 0.05]. No other significant associa-
tions were observed between ACT treatment and the
potential predictors tested in the model.
Discussion
Overall, our results underscore the high prevalence of
febrile episodes responsible for high health services
utilization and antimalarials use in both adults and chil-
dren. A third of households reported at least one recent
episode of fever. Over 90% of individuals with acute fever
received treatment outside the home and reported using
medicines, two-third of them received antimalarials. Pub-
lished reports suggest a decrease in the true prevalence
of malaria in Sub-Saharan Africa at the time of the sur-
veys, well before the dissemination of rapid diagnostic
testing (RDT) [19,20]. Yet, the use of antimalarials was
very high in all five surveys irrespective of geographic loca-
tion, socioeconomic status or age. Our results document
widespread presumptive antimalarial treatment for febrilesymptoms, a practice responsible for antimalarial overuse
and emergence of antimalarial resistance. They highlight
the importance of restricting antimalarials to diagnosed
cases of malaria with the use of RDTs, as recommended
by current WHO guidelines [21].
A key finding was the poor compliance of African
communities with national policies recommending ACT
as first line treatment for uncomplicated episodes of
malaria. When the surveys took place in 2007–2008, na-
tional ACT policies had been implemented for at least
three years in four of the five countries, and yet we
found that ACT was used in only 16% of the reported
febrile episodes. Our results document the gap between
pharmaceutical policies in place and the reality on the
ground. The highest observed ACT use was in Ghana
where only 32% of individuals taking antimalarials re-
ceived AS-AQ, which had been first-line treatment of
malaria for four years. In addition, several instances of
inappropriate artemisinin monotherapy were reported in
the four countries where ACT was available and the use
of halofantrine was documented in the Nigeria survey
despite its ban one year earlier [12].
Results from recent ACTwatch surveys suggest that the
majority of children under 5 years old with acute fever are
treated at home or in the private sector [22]. However,
our analysis of the WHO household surveys indicates
that more than half of individuals complaining of fever
seek care in public healthcare facilities. This difference
Table 4 Predictors of seeking care in a public healthcare facility, of receiving an antimalarial, and of receiving ACT





Number of observations 1686 1686 1257
OR(95% CI) OR(95% CI) OR(95% CI)
Household-related predictors
Sought care in a public health care facility - 1.67*** 4.64***(2.98,7.22)
Non-capital region (vs capital region) 2.14***(1.36,3.37) 1.52*(1.00,2.30) 0.93(0.40,2.15)
Total monthly expenditure in lowest quintile (vs higher) 0.92(0.66,1.30) 0.80(0.59,1.09) 1.04(0.72,1.49)
Distance from public hospital or health facility (vs <15min)
15 minutes to 1 hour 0.40***(0.29,0.56) 0.95(0.68,1.33) 0.79(0.52,1.21)
Over 1 hour 0.21***(0.14,0.33) 0.65*(0.43,0.98) 0.72(0.37,1.40)
Distance from private hospital, clinic, or doctor (vs <15min)
15 minutes to 1 hour 1.49*(1.02,2.16) 1.14(0.82,1.60) 1.02(0.63,1.66)
Over 1 hour 2.75***(1.91,3.98) 1.13(0.79,1.62) 1.15(0.65,2.02)
Distance from private medicines retail outlet (vs <15min)
15 minutes to 1 hour 1.20(0.83,1.75) 1.16(0.80,1.67) 1.42(0.84,2.41)
Over 1 hour 1.57**(1.06,2.33) 0.80(0.53,1.20) 1.56(0.89,2.71)
Respondent education high school or above (vs less or none) 0.91(0.64,1.28) 1.17(0.79,1.74) 2.67***(1.74,4.11)
Respondent opinions (vs no or unsure)
Closet public facility usually has medicines 1.47*(1.09,1.99) 1.25(0.92,1.71) 1.03(0.69,1.54)
free medicines at public facility 1.91***(1.45,2.51) 0.80(0.59,1.07) 1.20(0.77,1.88)
Can usually medicines needed 0.65**(0.48,0.89) 1.20(0.87,1.66) 0.96(0.66,1.40)
Patients -related predictors
Female (vs male) 0.90(0.71,1.13) 0.90(0.70,1.16) 0.87(0.65,1.17)
Age (vs 15 and over)
Under 5 years 1.34(0.99,1.80) 1.28(0.91,1.79) 0.80(0.57,1.13)
5-15 years 1.07(0.76,1.51) 1.21(0.80,1.83) 1.07(0.70,1.64)
Associate symptoms (vs no)
URI (cough, runny nose, sore throat, earache) 0.95(0.72,1.25) 0.59***(0.44,0.79) 0.68*(0.48,0.99)
Diarrhea, vomiting, nausea, could not eat 0.99(0.73,1.35) 1.40*(1.01,1.94) 1.40(0.97,2.02)
Difficulty breathing, fast breathing 1.41(0.85,2.37) 0.88(0.56,1.40) 0.76(0.43,1.35)
Other symptomes 0.73*(0.54,0.98) 0.61***(0.46,0.82) 0.99(0.65,1.51)
Perceived illness severity (vs mild)
Moderate 1.36*(1.02,1.82) 1.82***(1.38,2.40) 1.32(0.82,2.10)
Severe 1.46*(1.01,2.11) 1.39(0.9,2.12) 0.83(0.48,1.44)
*p<0.05, **p< 0.01, ***p<0.001.
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The WHO surveys seek to draw a broader picture of com-
munity treatment decisions about seeking care and obtain-
ing medicines. They apply no restrictive criteria to the
random selection of households, collecting information on
all household members, all their recent symptoms, and all
medicines taken and kept at home. ACTwatch surveys
strictly focus on children under 5 years old, excluding
households without febrile children under 5 years old. In
the five surveys we analyzed, only 39% of individuals withfever were children under 5 years old. In addition, the
ACTwatch instrument attempts to capture the iterative
steps that caregivers go through from the first recognition
of fever in a child, while the WHO survey examines medi-
cines use during the entire episode of illness [23].
Our study indicates that half of febrile episodes were
seen in public healthcare facilities. This highlights the crit-
ical role played by the public sector in treating common
ailments in communities, evidence that needs to be taken
into account when designing programs to strengthen
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health professionals in the public sector were more likely
than other healthcare providers to prescribe antimalarials
and ACT; seeking care in a public healthcare facility not
only increased the odds or receiving an antimalarial but
was the most important determinant of receiving ACT
at the time of the surveys, a result concordant with
other recent reports [12,24]. Of concern, children under
5 years old, who are more vulnerable to severe disease
and most in need of proper antimalarial treatment, had
a slightly lower likelihood of receiving ACT than adults
even though their likelihood of visiting a public health-
care facility and receiving antimalarials was somewhat
higher. This finding could be related to the lack of ap-
propriate ACT pediatric formulations at the time of the
surveys. It advocates for systematically evaluating the
effects of antimalarial policies in the entire community,
in order to identify unintended consequences that may
occur in key subgroups.
Our results illustrate how much perceptions about the
health system shape healthcare behaviors of households,
in particular opinions about where medicines can be
best accessed, where they are most affordable, and which
providers are best suited to treat more severe symptoms.
As expected, convenience also played a role: households
were more likely to seek care in a public facility when it
was close by and when they lived in less densely popu-
lated areas where public facilities often are the only
available source of care. Notably, we did not find an
association between living in less densely populated re-
gions and access to ACT, despite the higher use of pub-
lic health facilities in these areas. A possible explanation
is that public facilities in capital regions may have had a
better supply of ACT at the time of the surveys, al-
though this cannot be determined from our data.
The strong relationship between education and ACT
use is consistent with evidence that people with higher
education exhibit better recall of antimalarial names [25].
The presence of associated URI symptoms may increase
the likelihood of receiving antibiotics at the expenses of
antimalarials, as previously reported [15], which would ex-
plain the negative association between URI symptoms and
any type of antimalarial treatment.
Finally, our results indicate that national ACT policies
did not discriminate against the poor at the time of the
surveys when program implementation was largely con-
fined to the public sector. This goes against early con-
cerns about ACT not reaching the poor; however, this
situation may have changed since then and evidence of
inequity is emerging with the recent development of pri-
vate channels for ACT access [13,26].
The standardized WHO methodology to measure ac-
cess to and use of medicines in communities of low- and
middle-income countries with rapid sample surveys hasseveral limitations in design, including underrepresenta-
tion of hard to reach areas, as well as potential variance
underestimation, misclassification of households in
socio-economic brackets, and underestimation of self-
medication [15]. In addition, the survey depends on the
respondents’ identification of medicines used; about a
third of antimalarials were reported as “antimalarial,”
which may have resulted in an underestimation of ACT
use. While the WHO surveys did not have a special focus
on malaria, results are consistent with other surveys focus-
ing on ACT coverage [27-29]. They also provide valuable
information about determinants of care seeking and
patterns of antimalarial use in the early years of ACT na-
tional policy implementation. Such surveys can be recom-
mended as affordable strategies to assess the community
impact of future national policy changes to eradicate mal-
aria, such as malaria immunization campaigns [30].
Conclusion
Access to ACT remained limited in five African coun-
tries in the early years of national policies encouraging
its use as first-line treatment for malaria. It was largely
confined to public sector health facilities where many
households sought more affordable care. Since house-
holds continue to use antimalarials to treat most febrile
episodes, there is a critical need for expanded use of
RDT to guide appropriate treatment by community pro-
viders and caregivers.
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